Blood Pressure Kidney Disease Pharmacology 
DAIC
APRIL 7, 2024
Akshay Desai, MD “Compared to placebo, a single injection of zilebesiran resulted in clinically meaningful reductions in blood pressure at three months when added to commonly used antihypertensive treatments,” said Akshay Desai, MD, MPH , a cardiologist at Brigham and Women’s Hospital in Boston and a study coauthor. “In
Cardiometabolic Health Congress
JULY 10, 2024
Bakris’s distinguished career in medicine spanned over four decades, marked by significant contributions to the fields of diabetic kidney disease, hypertension, and nephropathy progression. His work was particularly influential in understanding racial disparities in disease progression and developing targeted interventions.
DAIC
MAY 16, 2024
Among those ages 65 and older, nearly 50% who underwent limb amputation died within one year after surgery, according to the 2024 Heart Disease and Stroke Statistics: A Report of U.S. Pharmacological and behavioral-based strategies often increase the smoking cessation rate in people with PAD, however, these strategies are underused.
Cardiometabolic Health Congress
JULY 25, 2023
Based on these results, updated diabetes guidelines recommend that in T2D patients with atherosclerotic cardiovascular disease, we should use GLP-1 RAs, and in T2D patients with heart failure or chronic kidney disease, we should use an SGLT-2 inhibitor after first-line therapy with lifestyle and metformin [25]. Diabetes Care 42.Supplement
DAIC
JANUARY 23, 2024
11 Despite the link between inflammation and cardiovascular disease has been proven by extensive research, most physicians have focused on treating high-risk patients with lipid lowering therapies including statin therapy.1,12,13 Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. μ/L on 0.6
Expert insights. Personalized for you.
111 
Let's personalize your content